Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation

被引:25
作者
Chin, C
Feindel, C
Cheng, D
机构
[1] Univ Toronto, Toronto Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Toronto Hosp, Div Cardiovasc Surg, Toronto, ON M5G 2C4, Canada
关键词
preoperative; amiodarone; heart transplant; postoperative; mortality;
D O I
10.1016/S1053-0770(99)90008-3
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective: To assess the effect of preoperative amiodarone treatment on patient mortality after heart transplantation. Design: Retrospective study. Setting: Single-institution university hospital. Participants: One hundred six consecutive patients with heart transplants. Interventions: None. Measurements and Main Results: Patients were grouped according to duration of preoperative amiodarone treatment, and posttransplant mortality before hospital discharge was compared with patients not treated with amiodarone, The authors collected cardiovascular data in the preoperative and postoperative periods. There was a significant increase in posttransplant mortality before hospital discharge in patients treated with amiodarone for more than 4 weeks in the preoperative period (p < 0.05), Patients treated with amiodarone had significantly lower (p < 0.05) heart rates (mean heart rate, 103 +/- 19 beats/min) in the early postoperative period than patients not treated with amiodarone (mean heart rate, 111 +/- 15 beats/min), but there was no relationship with mortality (p = not significant). Patients who died had a significantly lower (p < 0.05) postoperative cardiac index (2.2 +/- 0.7 to 2.5 +/- 0.7) in the first 24 hours after cardiopulmonary bypass compared with patients who survived to hospital discharge (3.0 +/- 0.7 to 3.1 +/- 0.9), but there was no relationship to amiodarone treatment (p = not significant). Conclusion: Preoperative amiodarone treatment for more than 4 weeks may be associated with a significant increase in postoperative mortality in patients undergoing heart transplantation. Therefore, the indications for amiodarone must be carefully considered and, if needed, the maintenance dose should be kept to a minimum. Copyright (C) 1999 by W.B. Saunders Company.
引用
收藏
页码:562 / 566
页数:5
相关论文
共 29 条
[1]  
ADDONIZIO LJ, 1987, CIRCULATION, V76, P52
[2]  
BOURGE RC, 1993, J HEART LUNG TRANSPL, V12, P549
[3]   AMIODARONE FOR MAINTENANCE OF SINUS RHYTHM AFTER CONVERSION OF ATRIAL-FIBRILLATION IN THE SETTING OF A DILATED LEFT ATRIUM [J].
BRODSKY, MA ;
ALLEN, BJ ;
WALKER, CJ ;
CASEY, TP ;
LUCKETT, CR ;
HENRY, WL .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (07) :572-575
[4]  
CAMPANA C, 1993, J HEART LUNG TRANSPL, V12, P756
[5]   AMIODARONE THERAPY DOES NOT COMPROMISE SUBSEQUENT HEART-TRANSPLANTATION [J].
CHELIMSKYFALLICK, C ;
MIDDLEKAUFF, HR ;
STEVENSON, WG ;
KOBASHIGAWA, J ;
SAXON, LA ;
MORIGUCHI, J ;
BROWNFIELD, ED ;
HAMILTON, MA ;
DRINKWATER, D ;
LAKS, H ;
STEVENSON, LW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 20 (07) :1556-1561
[6]  
CHENG DCH, 1998, ANAESTHESIA INTENSIV, P77
[7]  
COSTARDJACKLE A, 1991, CIRCULATION, V84, P329
[8]   Low-dose amiodarone-related complications after cardiac operations [J].
Dimopoulou, I ;
Marathias, K ;
Daganou, M ;
Prapas, S ;
Stavridis, G ;
Khoury, M ;
Geroulanos, S ;
Cokkinos, DV .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (01) :31-37
[9]   RISK-FACTORS FOR TOTAL AND CAUSE-SPECIFIC MORTALITY IN HUMAN CARDIAC TRANSPLANTATION - PROLONGED EXTRACORPOREAL BYPASS TIME - A HIGH-RISK FACTOR FOR REJECTION AND INFECTION [J].
FOERSTER, A ;
ABDELNOOR, M ;
GEIRAN, O ;
LINDBERG, H ;
SIMONSEN, S ;
THORSBY, E ;
FROYSAKER, T .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1991, 5 (12) :641-647
[10]   AMIODARONE FOR REFRACTORY ATRIAL-FIBRILLATION [J].
GOLD, RL ;
HAFFAJEE, CI ;
CHAROS, G ;
SLOAN, K ;
BAKER, S ;
ALPERT, JS .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (01) :124-127